News Daiichi Sankyo Company, Limited

Equities

4568

JP3475350009

Pharmaceuticals

Market Closed - Japan Exchange Other stock markets 12:00:00 13/04/2026 pm IST			5-day change	1st Jan Change
2,731.50 ^JPY	-1.48%		-4.43%	-18.41%

08/04	Atlatl Innovation Center And Daiichi Sankyo Enter Agreement To Deepen Apac Biotech Innovation	CI
02/04	Astrazeneca plc Announces Positive High-Level Results from the Emerald-3 Phase III Trial	CI

All News

08/04	Atlatl Innovation Center And Daiichi Sankyo Enter Agreement To Deepen Apac Biotech Innovation	CI
02/04	Astrazeneca plc Announces Positive High-Level Results from the Emerald-3 Phase III Trial	CI
02/04	Adlai Nortye Ltd. Announces President Changes, Effective April 1, 2026	CI
01/04	Nuvation Bio announces acquisition of Japan rights to safusidenib from Daiichi Sankyo	RE
01/04	Nuvation Bio Inc. Amends Exclusive License Agreement with Daiichi Sankyo to Include Japan Rights for Safusidenib	CI
01/04	Nuvation Bio Receives Global Rights to Safusidenib, Expands Phase 3 Trial Into Japan	MT
30/03	Guardant Health?s InfinityAI Real-World Evidence Supports Approval of ENHERTU® for Previously Treated Patients with HER2-Positive Metastatic Solid Tumors in Japan	CI
30/03	Final dividend	FA
27/03	Daiichi Sankyo : ENHERTU® Followed by THP Approved in China as the First and Only HER2 Directed ADC for the Neoadjuvant Treatment of HER2 Positive Breast Cancer	PU
25/03	Tempus announces strategic collaboration with Daiichi Sankyo to advance AI-driven biomarker discovery and clinical differentiation across an ADC clinical program	RE
25/03	Tempus Ai, Inc. and Daiichi Sankyo Enter Strategic Collaboration to Advance Ai-Driven Biomarker Discovery and Clinical Differentiation Across an Adc Clinical Program	CI
25/03	Tempus Announces Strategic Collaboration with Daiichi Sankyo to Advance AI-Driven Biomarker Discovery and Clinical Differentiation Across an ADC Clinical Program	BU
25/03	Tranche Update on Daiichi Sankyo Company, Limited's Equity Buyback Plan announced on April 25, 2025.	CI
25/03	Daiichi Sankyo : Announces Rescheduling of 5-year Business Plan (FY2026 - FY2030) Presentation & Discussion	PU
24/03	Daiichi Sankyo Company, Limited's Equity Buyback announced on April 25, 2025, has closed with 31,457,200 shares, representing 1.70% for ¥91,846.79 million.	CI
24/03	Daiichi Sankyo's cancer drug approved as second-line therapy in Japan	AN
23/03	Person Gulf War Drums Unnerve Asian Stock Markets	MT
23/03	Daiichi Sankyo : ENHERTU® Now Available in Japan as First Antibody Drug Conjugate for the Second-Line Treatment of Patients with HER2 Positive Metastatic Gastric Cancer	PU
23/03	Daiichi Sankyo : ENHERTU® Approved in Japan as First Tumor Agnostic HER2 Directed Medicine for Previously Treated Patients with HER2 Positive Metastatic Solid Tumors	PU
23/03	Daiichi Sankyo Announces Enhertu Approved in Japan as First Tumor Agnostic Her2 Directed Medicine for Previously Treated Patients with Her2 Positive Metastatic Solid Tumors	CI
18/03	Leveragen collaboration with Daiichi Sankyo to support development of advanced biologics using next-gen in vivo antibody discovery platforms	RE
18/03	Leveragen and Daiichi Sankyo Enter Research Collaboration Agreement	CI
17/03	Voro Therapeutics Announces Research Collaboration with Daiichi Sankyo to Advance PrimeBody? Technology for Next-Generation Tumor-Activated ADCs	CI
17/03	Japan's Nikkei falls a 4th day tech shares weigh, oil surges	RE
11/03	FDA Grants Priority Review to ENHERTU in Post-Neoadjuvant HER2-Positive Early Breast Cancer: A Market-Shaping Milestone \| AstraZeneca and Daiichi Sankyo	AQ